These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27743113)

  • 41. Retinal Pigment Epithelial Tear After Intravitreal Ranibizumab Treatment for Retinal Angiomatous Proliferation.
    Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
    Am J Ophthalmol; 2015 Nov; 160(5):1000-1005.e2. PubMed ID: 26210865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB; Lund-Andersen H; Sander B; Larsen M
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
    Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
    Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
    Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
    Lee JY; Chung H; Kim HC
    Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.
    Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM
    Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation.
    Chou HD; Wu WC; Wang NK; Chuang LH; Chen KJ; Lai CC
    BMC Ophthalmol; 2017 Jun; 17(1):104. PubMed ID: 28655307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
    Boulanger-Scemama E; Sayag D; Ha Chau Tran T; Quaranta-El Maftouhi M; Rumen F; Creuzot-Garcher C; Blanco Garavito R; Jung C; Souied E
    J Fr Ophtalmol; 2016 Oct; 39(8):668-674. PubMed ID: 27609025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary results of aflibercept in treatment-naive choroidal neovascularization of wet age-related macular degeneration.
    Gambon R; Barthelmes D; Amstutz C; Fleischhauer J; Kurz-Levin M; Zweifel S
    Klin Monbl Augenheilkd; 2014 Apr; 231(4):423-6. PubMed ID: 24771183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
    Ladaique M; Dirani A; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Ophthalmologica; 2015; 234(1):33-9. PubMed ID: 26112059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
    Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
    Berg K; Roald AB; Navaratnam J; Bragadóttir R
    Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.